| Identification | Back Directory | [Name]
1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt | [CAS]
157124-84-0 | [Synonyms]
BPH-652
FIOQVVKPUBNHEM-UHFFFAOYSA-N
1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt | [Molecular Formula]
C16H16K3O7PS | [MDL Number]
MFCD25976798 | [MOL File]
157124-84-0.mol | [Molecular Weight]
500.628 |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, away from moisture | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water : 25 mg/mL (49.94 mM; Need ultrasonic) |
| Hazard Information | Back Directory | [Uses]
BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1]. | [in vivo]
BPH-652 treatment (0.5 mg twice per day (days ?1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureusbacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group[1]. | Animal Model: | A systemic S. aureus infection model in mice[1]. | | Dosage: | 0.5 mg twice per day (days ?1, 0, 1, and 2). | | Administration: | Intraperitoneal injection. | | Result: | S. aureus bacterial counts in the kidneys of the mice treated with BPH-652 were significantly lower than those of the control group. |
| [References]
[1] Liu CI, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science. 2008 Mar 7;319(5868):1391-4. DOI:10.1126/science.1153018 |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|